"At Novo Nordisk, we believe that partnerships, based on long-term commitment and mutual interest, are key to fostering innovation. We work closely with universities and biotech companies worldwide to bring about innovation."

Mads Krogsgaard Thomsen,
Chief Science Officer
of Novo Nordisk
... interested in novel targets and innovative compounds and technologies that address unmet medical needs and have the potential to be disease modifying and to improve the life of patients. We are interested in development stages from target identification to clinical stage.

**Diabetes**
- Novel modalities that show, for example, insulin sensitisation, glucose regulation with added benefit on weight or comorbidities, improvement of beta-cell health
- Next generation insulin and GLP-1 receptor agonists with added benefit to glucose control, i.e. weight or comorbidities
- Novel modalities addressing immunotolerance for type 1 diabetes

**Obesity**
- Novel modalities that affect appetite regulation or energy expenditure
- Novel modalities that show improvement in lean body mass by fat loss
- Novel modalities that address comorbidities, e.g. diabetes, cardiovascular disease and/or NASH pathways and mechanisms of action that impact breakthrough weight loss (>15%)

**Haemophilia**
- Novel bypassing agents for prophylaxis
- Cell and gene-based therapy approaches
- Clinical assets in haematological disorders

**Other serious chronic cardio-metabolic diseases**
- **NASH**: Novel modalities that address fibrosis and inflammation
- **Atherosclerosis**: Novel modalities with potential to address residual risk in patients with high cardiovascular risk on top of cholesterol lowering therapies
- **Chronic heart failure**: Novel modalities with potential to add significant benefit on top of standard of care in patients with systolic or diastolic dysfunction
- **Chronic kidney disease**: Novel modalities addressing fibrosis or inflammation with potential to deliver efficacy on top of standard of care

**Other focus areas**
- Cell therapies (stem cell) or differentiation protocols for chronic serious diseases
- Cell encapsulation technologies
- Novel platforms for oligonucleotide or RNA-based therapies
- Peptide and protein technology platforms (expression, purification and modification)
- Formulation and drug delivery technologies with focus on oral delivery
- Exosomes and other cell-penetrating technologies

**at novo nordisk, we ...**

... innovate to improve the life of patients and drive growth

... aim to lead in all disease areas in which the company is active

... have the capabilities to bring your idea towards an innovative treatment

... build sustainable relations for long-term collaborations based on trust

... are flexible in our engagement models
our search & evaluation team

Headquarters

Miriam Frieden
Vice President
mmfi@novonordisk.com

Matthew Coghlan
NASH, Obesity, CKD
mwcg@novonordisk.com

Tomas Landh
Diabetes
tolh@novonordisk.com

Neil Anderson
Stem cell, Haemophilia
nlao@novonordisk.com

Zaki Salanti
CVD
zaks@novonordisk.com

Regional responsibilities

Aaron Schwartz
Boston/Technologies
aswr@novonordisk.com

Chuck Gray
USA
cg@novonordisk.com

Florence Dal Degan
Europe
fdd@novonordisk.com

Xichen Lin
Asia/Pacific
xclin@novonordisk.com
“At Novo Nordisk, we believe that partnerships, based on long-term commitment and mutual interest, are key to fostering innovation. We work closely with universities and biotech companies worldwide to bring about innovation.”

Mads Krogsgaard Thomsen, Chief Science Officer of Novo Nordisk

---

**our search & evaluation team**

### Headquarters

- **Miriam Frieden**
  - Vice President
  - mmf@novonordisk.com

- **Matthew Coghlan**
  - NASH, Obesity, CKD
  - mwcp@novonordisk.com

- **Neil Anderson**
  - Stem cell, Haemophilia
  - nlao@novonordisk.com

- **Tomas Landh**
  - Diabetes
  - tolh@novonordisk.com

- **Zaki Salanti**
  - CVD
  - zaks@novonordisk.com

### Regional responsibilities

- **Aaron Schwartz**
  - Boston/Technologies
  - aswr@novonordisk.com

- **Chuck Gray**
  - USA
  - cg@novonordisk.com

- **Florence Dal Degan**
  - Europe
  - fdd@novonordisk.com

- **Xichen Lin**
  - Asia/Pacific
  - xclin@novonordisk.com

---

**we partner for innovation**